Frank Mccormick - 22 Jun 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 22 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 18:05:29 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Frank Mccormick filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 24 Jun 2026.

Key facts

This page summarizes Frank Mccormick's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2026, 18:05.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001257809 Primary reporting owner

MCCORMICK FRANK

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Award

Transaction value
Shares: +3,990
Change %: +61%
Price: $0.000000^*
Shares after: 10,579
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 756,665
Date: 22 Jun 2026
Ownership: By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Footnotes: F3, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,277
Change %
Price: $0.000000^*
Shares after: 5,277
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,277
Exercise price: $68.92
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.

Footnote F4

Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.

Footnote F5

Includes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.

Footnote F6

The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.